These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6126231)

  • 21. Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels.
    Garver DL
    J Clin Psychopharmacol; 1989 Aug; 9(4):277-81. PubMed ID: 2570087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels.
    Aymard N; Baldacci C; Leyris A; Smagghe PO; Tribolet S; Vacheron MN; Viala A; Caroli F
    Therapie; 1997; 52(3):227-32. PubMed ID: 9366107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A radioreceptor assay for neuroleptic drugs in plasma.
    Lader SR
    J Immunoassay; 1980; 1(1):57-75. PubMed ID: 6112242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.
    Wong JO; Leung SP; Mak T; Ng RM; Chan KT; Hon-Kee Cheung H; Choi WK; Lai J; Wai-Kiu Tsang A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):251-64. PubMed ID: 16316716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
    Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
    Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.
    Smith RC; Crayton J; Dekirmenjian H; Klass D; Davis JM
    Arch Gen Psychiatry; 1979 May; 36(5):579-84. PubMed ID: 35115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evoked visual responses in schizophrenic patients].
    Libiger J; Kuba M; Zapletálek M
    Cesk Psychiatr; 1992 Aug; 88(3-4):148-53. PubMed ID: 1356080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels.
    Tang SW
    Can J Psychiatry; 1985 Jun; 30(4):249-50. PubMed ID: 2861888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.
    Tune LE; Creese I; DePaulo JR; Slavney PR; Snyder SH
    J Nerv Ment Dis; 1981 Jan; 169(1):60-3. PubMed ID: 6108981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.
    Cooper SF; Albert JM; Hillel J; Caille G
    Curr Ther Res Clin Exp; 1973 Feb; 15(2):73-7. PubMed ID: 4632509
    [No Abstract]   [Full Text] [Related]  

  • 40. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
    Rao ML; Brown WA
    Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.